Steven Kelly Named President And CEO, Innovive Pharmaceuticals, Inc.

NEW YORK, Dec. 1 /PRNewswire/ -- Steven Kelly, has been named president and chief executive officer of Innovive Pharmaceuticals, Inc., a biopharmaceutical company headquartered in New York City. Innovive Pharmaceuticals was established in 2004 to acquire, develop and commercialize novel therapeutics in oncology and hematology.

Mr. Kelly brings over fifteen years experience in a variety of commercial roles in biotechnology and pharmaceutical companies.

Prior to joining Innovive, Mr. Kelly headed the newly created oncology marketing group for Sanofi-Synthelabo's US division, where he led the launch of Eloxatin(TM), the pharmaceutical industry's most successful anti-cancer product launch to date. Eloxatin is used in the treatment of colorectal cancer.

Mr. Kelly joined Sanofi from IDEC Pharmaceuticals. While at IDEC as Director of Marketing, Mr. Kelly led the launch of Rituxan(R) in a co-promotion agreement with Genentech. Rituxan, a treatment for Non-Hodgkin's lymphoma, has become one of the leading anticancer therapies in the U.S.

Prior to IDEC, Mr. Kelly worked at Amgen, where he held various positions, including roles in Epogen(R) marketing, new products marketing, and manufacturing.

Steven Kelly holds an MBA from Cornell University and a B.S. in Biology and Chemistry from the University of Oregon.

Innovive Pharmaceuticals, Inc. is a privately held biopharmaceutical company headquartered in New York, N.Y. The company's mission is to acquire, develop and commercialize novel therapeutics addressing significant unmet medical needs in the fields of oncology and hematology. For additional information visit http://www.innovivepharma.com/.

Innovive Pharmaceuticals, Inc.

CONTACT: Jon Weisberg, +1-435-658-0910, or cell, +1-435-640-2994, orfax, +1-435-658-5299, jonweisberg@inkandair.com, for Innovive Pharmaceuticals,Inc.

Back to news